RxDoctor Payments Data

Edgar Sanchez, MD

Infectious Disease · Orlando, FLNPI 1033347810

Payments from drug & device makers

$2,125in general payments, 2019–2025

Across 17 payments — averaging $124.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shionogi Inc$1K
  • Paratek Pharmaceuticals, Inc.$162
  • Viiv Healthcare Company$147
  • Insmed, Inc.$116
  • Invivyd Inc$111
  • Ferring Pharmaceuticals Inc.$105
  • plus $158 from 4 others

What the payments were for

  • Consulting fees$1,20056%
  • Food & beverage$80838%
  • Education$1165%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,125 in reported general payments places this provider in the 65th percentile of 669 infectious disease providers in Florida.

See all infectious disease providers in Florida

Medicare billing

Part B allowed, 2024
$119,468
Medicare patients
340
Services billed
1,278

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala77$318,793
ArikayceAmikacin Liposomal/Neb.Accessr14$214,758
CabenuvaCabotegravir/Rilpivirine13$88,349
JulucaDolutegravir/Rilpivirine17$57,979
TivicayDolutegravir Sodium21$44,975
OdefseyEmtricitab/Rilpiviri/Tenof Ala11$44,970
PrezcobixDarunavir/Cobicistat16$39,027
Gamunex-CImmune Globul G/Gly/Iga Avg 4612$27,691
Daptomycin23$10,221
CeftriaxoneCeftriaxone Sodium17$2,136
Cefepime Hcl11$1,897
Methenamine Hippurate22$1,563
Ethambutol Hcl12$1,346
Doxycycline Hyclate22$367
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim16$200

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$101$318,79377 claims
Insmed, Inc.Arikayce$116$214,75814 claims
Viiv Healthcare CompanyCabenuva, Juluca, Tivicay$147$191,30251 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 669 infectious disease providers in Florida.

Other infectious disease in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →